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Abstract
AIM: To evaluate the correlation between serum vascular
cellular adhesion molecule-1 (VCAM-1) levels and
clinicopathological features in patients with hepatocellular
carcinoma (HCC).
METHODS: Ninety-six patients who underwent HCC
resection were recruited in the study. Preoperative serum
levels of soluble VCAM-1 were measured by enzyme-linked
immunosorbent assay.
RESULTS: Serum VCAM-1 level in HCC patients was
inversely correlated with platelet count (r=-0.431, P<0.001)
and serum albumin level (r=-0.279, P<0.001), and positively
correlated with serum bilirubin level (r=0.379, P<0.001).
Serum VCAM-1 level was not associated with tumor
characteristics such as tumor size, venous invasion,
presence of microsatellite nodules, tumor grade and tumor
stage. Serum VCAM-1 level was significantly higher in HCC
patients with cirrhosis compared with those without cirrhosis
(median 704 vs 546 ng/mL, P<0.001). Furthermore, a
significantly better disease-free survival was observed in
HCC patients with low VCAM-1 level (P=0.019).
CONCLUSION: Serum VCAM-1 level appears to reflect
the severity of underlying chronic liver disease rather than
the tumor status in HCC patients, and low preoperative
serum VCAM-1 level is predictive of better disease-free
survival after surgery.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a tumor characterized by a
rich vasculature. The formation of rich vasculature depends on
angiogenesis, which is a process that plays an important role
in tumor progression, growth, and metastasis. Many angiogenic
factors and mediators are involved in the control of angiogenesis.
       Vascular cell adhesion molecule-1 (VCAM-1) is one of the
adhesion molecules that have been implicated as a mediator of
angiogenesis[1]. As one of the cell adhesion molecules in the
immunoglobulin superfamily, human VCAM-1 is Mr 100 000-
110 000, type 1 transmembrane glycoprotein[2-4]. VCAM-1 is
transiently expressed on activated vascular endothelial cells in
response to vascular endothelial growth factor (VEGF) and
other cytokines, such as tumor necrosis factor a, interleukin
1b, and interferon g[2,5-7]. Functionally, its expression plays a
major role in adhesion of leukocytes to the endothelium in
inflammed tissue and in the tumor site[2]. It also plays an
important role in providing attachment to the developing
endothelium during angiogenesis[8-10]. Furthermore, it may also
exert its function as an adhesion molecule to facilitate metastasis[2].
A previous study showed that VCAM-1 expression was
associated with the metastasis of melanoma[11].
       VCAM-1 is a soluble molecule that can be detected in the
circulation. Although the exact mechanism by which VCAM-1
is shredded into the bloodstream is unknown, it may involve
both proteolytic processing and alternative splicing[12,13].
Because VCAM-1 can be identified in bloodstream, it is
potentially useful as a non-invasive biomarker for the monitoring
of disease progression in cancer and other diseases[14-16]. It
has been reported that VCAM-1 is over-expressed in various
diseases and cancers. Recent studies have demonstrated high
serum levels of VCAM-1 in patients with colorectal cancer and
gastric cancer[16-17]. One study demonstrated that a high serum
VCAM-1 level was significantly associated with advanced
disease stage and the presence of distant metastasis in gastric
cancer[17]. A high serum VCAM-1 level has been shown to be
associated with angiogenesis and poor prognosis in breast
cancer[18]. A study has also found that serum VCAM-1 was an
independent prognostic marker in patients with Hodgkin’s
lymphoma[19].
       Up-regulated VCAM-1 expression in chronic liver disease
has also been reported, suggesting that VCAM-1 may play a
role in the pathogenesis of chronic hepatitis or cirrhosis[20-26].
Serum VCAM-1 levels higher than normal have been
consistently reported in several studies of chronic liver disease
of various etiologies[19-27]. However, the clinical significance of
serum VCAM-1 in HCC patients has not yet been reported
before. The majority of HCC patients have associated chronic
hepatitis or cirrhosis. It is of interest to study serum VCAM-1
in HCC patients because VCAM-1 may be involved in the
progression of both the tumor and the underlying chronic liver
disease.
      The objective of this study was to evaluate the levels of
serum soluble VCAM-1 in HCC patients compared with cirrhotic
patients without HCC and normal controls, and to analyze the
correlation of serum VCAM-1 level with clinicopathological
features in HCC patients.
MATERIALS AND METHODS
Patients
Ninety-six patients (71 men and 25 women; median age 55.5 years,
range 16-79 years) who underwent resection of HCC in the
Department of Surgery of the University of Hong Kong at Queen
Mary Hospital were studied. In the majority of cases (81%,
n=78), HCC was related to hepatitis B viral infection. None of
the 96 patients had received any preoperative treatment. The
study was approved by the Ethics Committee of our institution
and informed consent was obtained from the patients.
       Preoperative serum was collected from the patients. Venous
blood samples were drawn into a serum separator tube and
centrifuged at 3 000 r/min for 10 min, then stored at -80  until
VCAM-1 levels were determined. Serum samples were also
obtained from 19 healthy controls without evidence of any
active disease and 23 patients with cirrhosis but no evidence
of HCC on ultrasonography and alpha fetoprotein (AFP)
surveillance. The majority of the 23 cirrhotic patients (74%,
n=17) had cirrhosis related to hepatitis B viral infection.
Measurement of serum VCAM-1 level
Serum VCAM-1 levels were quantified using an enzyme-linked
immunosorbent assay kit designed to quantitatively measure
human soluble VCAM-1 concentration in serum (Human
sVCAM-1 Immunoassay; R&D systems, Minneapolis, MN).
This assay contains recombinant human VCAM-1 and
antibodies against the recombinant factor. The assay can
recognize both recombinant and natural human VCAM-1.
Briefly, 100 mL of diluted VCAM-1 conjugate (antibody to
recombinant VCAM-1 conjugated to horse-radish peroxidase)
was added to each well that was pre-coated with monoclonal
antibody specific for VCAM-1, after which, 100 mL of serially
diluted recombinant VCAM-1 standards and serum samples
were added to the wells and incubated at room temperature for
1.5 h. After the wells were washed with wash buffer 6 times to
clear any unbound substances, tetramethylbenzidine was added
to the wells for color development. The intensity of the
developed color was measured by reading absorbance at
450 nm. Each measurement was made in duplicate and the serum
VCAM-1 level was determined by extrapolation from a standard
curve generated for each set of samples assayed. The sensitivity
of the assay was 2 ng/mL, and the coefficients of variation of
intraassay and interassay determination were in the range given
by the manufacturer (4.3-5.9% and 8.5-10.2%, respectively).
Clinicopathologic and follow-up data
All clinicopathologic and follow-up data were prospectively
collected and entered into a computerized database. Detailed
preoperative blood tests such as complete blood count,
coagulation profile, liver biochemistry, indocyanine green
retention at 15 min (ICG15), serum AFP level, and hepatitis viral
serology were assessed for all patients. Histopathologic data
including Edmonson grade[28] (1-2 or 3-4), any venous invasion,
tumor capsule, microsatellite lesion and pTNM stage[29] (I/II or
III/IVA) were collected. All patients had a computed tomography
(CT) scan 1 mo after the hepatic resection to detect any tumor,
which was considered a residual disease. Patients who had a
positive margin or residual tumors in the 1-month CT scan were
considered having a palliative resection.
      Postoperative follow-up included monitoring for tumor
recurrence by monthly serum AFP level and chest X-ray
detection together with ultrasonography or computed
tomography (CT) scan every 3 mo. Recurrence of disease was
diagnosed by the detection of any intrahepatic or extrahepatic
tumor with a typical enhancement pattern of HCC in contrast
CT scan and elevation of serum AFP level on serial
measurements. Percutaneous fine-needle aspiration cytology
was performed to confirm the diagnosis of recurrence in
uncertain cases. Disease-free survival was calculated from the
date of hepatic resection to the date when recurrence was
diagnosed or, in the absence of detectable recurrence, to the
date of death or last follow-up.
Statistical analysis
Continuous data were expressed as median with range in
parenthesis. For comparison between groups, Mann-Whitney
U test was used for analysis of continuous variables, and Chi-
square test (or the Fisher’s exact test, where appropriate) was
used for analysis of discrete variables. Correlation analysis
was performed using the Spearman rank correlation test.
Cumulative disease-free survival was computed using the
Kaplan-Meier method and compared between groups by the
log-rank test. Serum VCAM level was entered into a multivariate
Cox regression analysis together with 7 other variables that
were demonstrated to be of prognostic importance in previous
studies from our center and others, namely, serum AFP level,
tumor size, presence of venous invasion, presence of
microsatellite nodules, presence of underlying cirrhosis and
pTNM stage[30,31]. All statistical analyses were performed using
the SPSS statistical software (SPSS/PC+, SPSS Inc., Chicago,
Illinois). P<0.05 was considered statistically significant.
RESULTS
Serum VCAM-1 levels
Figure 1 shows the distribution of serum VCAM levels in normal
controls (n=19), patients with cirrhosis only (n=23) and HCC
patients (n=96). The median serum VCAM-1 level in healthy
individuals, patients with cirrhosis only, and patients with HCC
was 631 ng/mL (449-1 103), 780 ng/mL (509-4 120), and 621 ng/mL
(179-3 199), respectively. There was no significant difference in
serum VCAM-1 levels between HCC patients and normal
individuals (P=0.447). However, there were significant
differences in serum VCAM-1 levels between cirrhotic patients
without HCC and normal individuals (P=0.010), and between
cirrhotic patients with and without HCC  (P<0.001).
Figure 1  Scatter plot to illustrate the distribution of serum
VCAM-1 level (ng/mL) in healthy control subjects (n=19), cir-
rhosis subjects without HCC (n=23), and HCC patients (n=96).
Correlation between serum VCAM-1 levels and clinicopathological
features in HCC patients
Preoperative serum levels of VCAM-1 in the 96 patients with
HCC were analyzed to identify any relationship with the
clinicopathological parameters. When analyzed in relation to
preoperative clinical parameters categorized as binary variables
(Table 1), serum VCAM-1 level had no significant relationship
with patients’ sex, age, hepatitis B surface antigen status, serum
AFP level or serum albumin level. However, serum VCAM-1
levels were significantly higher in patients with high ICG15
(>10%), which signifies impaired liver function, and in patients
with thrombocytopenia, which signifies the presence of
significant hypersplenism. When correlated as continuous
variables, serum VCAM-1 levels were positively correlated with
serum bilirubin level (r=0.379, P<0.001) and negatively
correlated with white cell count (r=-0.226, P=0.027), platelet
count (r=-0.431, P<0.001) and serum albumin level (r=-0.279,
P<0.001).
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Table 1  Preoperative serum VCAM-1 levels categorized by
clinical and laboratory variables
Variables    Median serum VCAM-1 (ng/mL)       P1
Gender
    Male (n=71) 623   0.381
    Female (n=25) 594
Age (yr)
    60 (n=56) 615   0.460
    >60 (n=40) 639
HBsAg
    Positive (n=78) 623   0.266
    Negative (n=18) 592
Serum AFP
    20 ng/mL (n=29) 608   0.737
    >20 ng/mL (n=67) 623
Serum albumin
    40 g/L (n=59) 614   0.228
    >40 g/L (n=37) 634
ICG15
    10% (n=45) 531 <0.001
    >10% (n=51) 667
Platelet count
    150 ×109 /L (n=44) 728 <0.001
    >150 ×109 /L (n=52) 547
HBsAg: Hepatitis B surface antigen; AFP: alpha-fetoprotein;
ICG15: indocyanine green retention at 15 min. 1By Mann-
Whitney U test.
Table 2  Preoperative serum VCAM-1 levels categorized by
pathological variables
Variables                      Median serum VCAM-1         P1
                                                           (ng/mL)
Background liver disease
Normal (n=7) 462
Chronic hepatitis (n=39) 548      0.0842
Cirrhosis (n=50) 704    <0.001b
Cirrhotic liver
Absent (n=46) 546    <0.001
Present (n=50) 704
Tumor size
5 cm (n=35) 686      0.158
>5 cm (n=61) 609
Tumor capsule
Absent (n=66) 597      0.015
Present (n=30) 736
Venous invasion
Absent (n=49) 643      0.248
Present (n=47) 574
Microsatellite nodules
Absent (n=50) 643      0.359
Present (n=46) 626
Edmonson grade
I/II (n=49) 634      0.629
III/IV (n=47) 642
pTNM stage
I/II (n=43) 649      0.134
III/IV (n=53) 592
pTNM: Pathological tumor-node-metastasis. 1By Mann-
Whitney U test; 2Compared with normal nontumorous liver;
bP<0.001 compared with both normal liver and chronic hepatitis.
      Table 2 shows the relationship of serum VCAM-1 levels
and histopathologic features of the resected HCC. There was
no significant relationship with the tumor size (P=0.185), the
presence of microsatellite tumor nodules (P=0.359) or venous
invasion (P=0.248). Significantly higher serum VCAM-1 levels
were observed with the presence of tumor capsule (P=0.015)
and the presence of cirrhosis in adjacent non-tumor liver tissues
(P<0.001). When categorized according to tumor pTNM staging
or Edmonson grading, no significant differences in serum VCAM-
1 levels were observed between different tumor stages or grades.
Serum VCAM-1 levels in HCC patients with or without cirrhosis
Fifty out of the 96 HCC patients had cirrhotic liver adjacent to
the resected tumor. The median level of serum VCAM-1 in
these cases of HCC with cirrhosis was 704 ng/mL (179-3 199),
which was significantly higher than that in the HCC cases
without cirrhosis (median 546 ng/mL, range 207-1 248, P<0.001),
but it was significantly lower than that in the 23 patients with
cirrhosis only (P=0.034). All patients with HCC and cirrhosis
had Child’s A liver function status, whereas among the 23 patients
with cirrhosis only, 8 patients were Child’s A, 7 patients were
Child’s B and 8 patients were Child’s C. When compared with
the healthy individuals, although the median level of serum
VCAM-1 in HCC patients with cirrhosis was higher, the
difference was not statistically different (P=0.271). In contrast,
HCC patients without cirrhosis (n=46) had a significantly lower
level of VCAM-1 when compared with healthy individuals
(P=0.008). HCC patients with chronic hepatitis (n=39) had a
higher serum VCAM-1 level than HCC patients with normal
liver, but the difference was not statistically significant (P=0.084).
Figure 2  Disease-free survival analysis of HCC patients segre-
gated into low ( 467 ng/mL, n=21) and high (>467 ng/mL,
n=67) preoperative serum VCAM-1 levels (P=0.019).
Prognostic value of serum VCAM-1 levels on disease-free survival
Excluding 8 patients with hospital mortality or palliative
resection, 88 patients were available for survival analysis to
determine the prognostic influence of serum VCAM-1 levels.
The median follow-up of the patients was 33 mo (range 15-52 mo).
Because of the skewed distribution of serum VCAM-1 levels
among the 88 patients, the 25 th percentile of VCAM-1 levels
(467 ng/mL) was used as a cut-off point of high and low values
of serum VCAM-1 levels in these patients[32]. At the time of
analysis, 52 of the 88 HCC patients had postoperative
recurrence. The disease-free survival was compared between
two groups of patients who were segregated in low (n=21) and
high (n=67) serum VCAM-1 levels. Patients with low levels of
VCAM-1 had significantly better disease-free survival than
those with high levels of VCAM-1 (3-year disease-free survival
66.7% vs 32.8%, P=0.019, Figure 2). The overall survival was
also better in the group with low serum VCAM-1 levels than in
the group with high levels, but the difference was not
statistically significant (3-year overall survival 75.0% vs 54.2%,
P=0.406).
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       Serum VCAM-1 was entered into a Cox regression analysis
of disease-free survival together with serum AFP (> or 20 ng/mL),
tumor size (> or 5 cm), presence of venous invasion, presence
of microsatellite lesions, presence of cirrhosis and tumor pTNM
stage. Only pTNM stage (risk ratio 1.409, 95% confidence
interval 1.080-1.840, P=0.012) and serum VCAM-1 (risk ratio
2.329, 95% confidence interval 1.045-5.191, P=0.039) were
significant prognostic factors for disease-free survival.
DISCUSSION
Evaluation of angiogenic factors has shown important clinical
implications in many types of cancer. In particular, the
measurement of various circulating angiogenic factors might
provide important prognostic values independent of
conventional pathological factors in cancer patients[33]. HCC is
a highly vascularized malignancy, and angiogenesis has been
known to be important for its development and metastasis[34].
Hence, it is of great interest to evaluate the clinical significance
of circulating angiogenesis-related markers in HCC patients.
Serum VCAM-1 appears to be a promising circulating marker
that might have a prognostic value in several types of cancer[16-19].
To our knowledge, this is the first study that evaluated the
clinical significance of serum VCAM-1 levels in HCC patients.
      Although the median level of VCAM-1 in HCC patients
appeared to be similar to that in normal subjects, within the
group of HCC patients, those with underlying cirrhosis had a
significantly higher VCAM-1 level than those with chronic
hepatitis or normal nontumorous liver. Furthermore, high serum
VCAM-1 levels in HCC patients correlated positively with
serum bilirubin level and inversely with serum albumin level
and platelet count. These findings suggested that high serum
VCAM-1 levels were related to the severity of underlying
chronic liver diseases. In contrast, there was no significant
relationship between serum VCAM-1 levels and tumor size,
pathological features of invasiveness or tumor stage. This
finding in HCC patients was contrary to the findings of higher
serum VCAM-1 levels associated with more advanced stage
tumors in other cancers[16-19]. Analysis of serum VCAM-1 levels
in HCC patients is complicated by the fact that most cases of
HCC are associated with chronic liver disease, which could
also contribute to the serum VCAM-1 levels. The source of
VCAM-1 in the circulation of HCC patients could come from
activated endothelial cells in both the tumor and chronic
hepatitis or cirrhosis in the nontumorous liver. Our study
suggested that serum VCAM-1 level in HCC patients could
reflect the severity of underlying chronic liver disease rather
than the tumor status. Unlike the case of some other cancers,
VCAM-1 may play a less important role as a mediator of
angiogenesis or related pathological processes in HCC. One of
the main functions of endothelial adhesion molecules in tumor
is to facilitate the adhesion of leukocytes into tumor
endothelium, which in turn could promote angiogenesis[35].
Yoong et al.[36] demonstrated that vascular adhesion protein-1
and intercellular adhesion molecule-1, rather than VCAM-1,
supported adhesion of tumor infiltrating lymphocytes to tumor
endothelium in HCC. In fact, the serum VCAM-1 levels of the
46 patients with HCC and noncirrhotic liver were significantly
lower than those of normal controls, suggesting that VCAM-1
expression may be down-regulated in HCC patients. While most
studies in other types of cancer reported the expression of
serum VCAM-1 levels was up-regulated, down-regulation of
VCAM-1 has also been reported in node positive breast cancer
patients[37].
      The serum VCAM-1 levels in the 96 HCC patients in this
study were significantly lower than those of 23 patients with
cirrhosis only. Even when the 50 patients with HCC and
background cirrhosis were separately analyzed, their serum
VCAM-1 levels were still significantly lower than those of the
23 patients with cirrhosis only. This is probably attributable to
the fact that all cirrhotic patients with HCC who underwent
hepatic resection had Child’s A cirrhosis, whereas the majority
of patients in the group with cirrhosis only had Child’s B or C
cirrhosis. Several previous studies have demonstrated that
serum VCAM-1 levels were elevated in cirrhotic patients
compared with normal controls, and that serum VCAM-1 level
was higher with more severe impairment of liver function or more
severe portal hypertension[22,23,26,27]. Two studies demonstrated
that serum VCAM-1 levels reflected the degree of fibrosis in
hepatitis C related cirrhotic patients[24,25]. Our study suggested
a similar relationship between serum VCAM-1 level and severity
of cirrhosis in a group of patients with predominantly hepatitis
B virus related cirrhosis. VCAM-1 appears to play an important
role in liver inflammation and fibrosis, probably by mediating
interaction between lymphocytes and endothelium. Further
studies to clarify the role of VCAM-1 in chronic liver disease
may lead to a better understanding of the pathogenesis of
cirrhosis and may provide a novel target of intervention to
prevent progression of cirrhosis.
      Although serum VCAM-1 level was not related to tumor
invasiveness or stage, we observed a significantly better
disease-free survival in HCC patients with low level of serum
VCAM-1. Our study demonstrated that preoperative circulating
level of VCAM-1 had a prognostic value in patients undergoing
resection of HCC independent of conventional prognostic
factors. The exact mechanism underlying the survival
differences between patients with low and high serum VCAM-
1 levels is unclear. In view of the relationship between serum
VCAM-1 levels and the severity of underlying chronic liver
disease or cirrhosis found in this study and other studies[22-27],
we speculate that the unfavorable prognostic influence of high
serum VCAM-1 level is likely to be related to the underlying
cirrhotic or fibrotic condition. The presence of cirrhosis or a
higher degree of liver fibrosis has been shown to predispose to
multicentric hepatocarcinogenesis and hence postoperative
recurrence of HCC[30,31]. An alternative possibility is that HCC
with significantly down-regulated VCAM-1 expression may be
associated with more favorable prognosis after resection.
However, the exact mechanism for the reduction in serum
VCAM-1 level in the presence of HCC observed in some patients
is far from clear, and such a possibility seems less likely in view
of the lack of association between serum VCAM-1 and tumor
characteristics. Further studies that correlate serum VCAM-1
level with the expression of VCAM-1 in HCC tumor tissues and
adjacent nontumorous liver may help clarify the mechanism
underlying the prognostic significance of serum VCAM-1 levels
in HCC patients. Irrespective of the underlying mechanism, the
predictive value of serum VCAM-1 level might have potential
clinical application in selecting patients with a higher risk of
postoperative recurrence for some adjuvant therapy to reduce
recurrence.
       In conclusion, our data demonstrated that serum VCAM-1
levels in HCC patients correlated with the impairment of liver
function and the presence of cirrhosis but not tumor size or
features of tumor invasiveness. Hence, serum VCAM-1 levels
appear to reflect the severity of underlying liver disease rather
than the tumor status in HCC patients. A low serum VCAM-1
level predicts better disease-free survival after tumor resection
in HCC patients. Further studies are merited to investigate the
exact mechanisms involved in these observations and to explore
the potential use of serum VCAM-1 level as a novel prognostic
marker in HCC patients.
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